Trodelvy 200 mg powder for concentrate for solution for infusion clinical trials
7 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic use (Phase IV)
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan
This study looks at the long-term safety of a treatment called Trodelvy for people with advanced cancers that have spread. It aims to see how safe the drug is when used over a longer period in patients who are already doing well on it.
For: Metastatic solid tumorsSpain · Belgium · France - Ongoing, recruitingTherapeutic exploratory (Phase II)
Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative or Luminal Breast Cancer. – The PRIMED Study –
This study, called PRIMED, is looking at ways to make a breast cancer medicine called Trodelvy easier to tolerate. It's for people with advanced triple-negative or HR+/HER2- breast cancer, focusing on reducing side effects like severe diarrhoea and low white blood cell counts.
For: Advanced triple-negative breast cancer (TNBC) · Advanced HR[+]/HER2[–] breast cancer.Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
An open label, single-arm, phase 2 study of neoadjuvant sacituzumab govitecan, before radical cystectomy, for patients with muscle-invasive bladder cancer who cannot receive or refuse cisplatin-based chemotherapy
This study is looking at a new medicine called Trodelvy for people with a type of bladder cancer that has grown into the muscle of the bladder. It's for those who can't have or don't want standard chemotherapy. Researchers want to see if Trodelvy helps shrink the cancer before surgery.
For: Muscle-invasive bladder cancerItaly - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Subjects with Metastatic or Locally Advanced Unresectable Urothelial Cancer
This study compares a new medicine called Sacituzumab Govitecan with standard treatments for advanced bladder cancer that has spread or can't be removed. Researchers want to see if the new medicine helps people live longer and feel better.
For: Locally Advanced or Metastatic Unresectable Urothelial CancerItaly · France · Sweden - AuthorisedTherapeutic exploratory (Phase II)
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE) [without IMPD-Q]
This study is for people with a type of lung cancer that can be removed with surgery. It looks at new treatments given before and after surgery to see if they can help shrink the cancer and stop it from coming back.
For: non-small cell lung cancerGermany - AuthorisedTherapeutic exploratory (Phase II)
Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystectomy patients: phase II trial (preSAVE trial)
This study looks at new treatments (Zimberelimab and Trodelvy) for muscle-invasive bladder cancer in people who can't have surgery or choose not to. We want to see how well these drugs can help control the cancer and avoid surgery.
For: Muscle-Invasive Bladder cancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)
This study is testing new drug combinations for advanced triple-negative breast cancer that has a specific marker called PD-L1. It aims to see if they are safe and help shrink tumours.
For: PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCERSpain